Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
109,628,845
-
Total 13F shares
-
49,783,588
-
Share change
-
+4,807,124
-
Total reported value
-
$188,178,786
-
Put/Call ratio
-
160%
-
Price per share
-
$3.78
-
Number of holders
-
120
-
Value change
-
+$19,456,848
-
Number of buys
-
59
-
Number of sells
-
58
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) as of Q4 2024
As of 31 Dec 2024,
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) was held by
120 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,783,588 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, VANGUARD GROUP INC, BANK OF AMERICA CORP /DE/, BlackRock, Inc., Almitas Capital LLC, CITADEL ADVISORS LLC, 683 Capital Management, LLC, GOLDMAN SACHS GROUP INC, and Boxer Capital Management, LLC.
This page lists
121
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.